期刊
JOURNAL OF VIROLOGY
卷 87, 期 24, 页码 13892-13899出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.02448-13
关键词
-
类别
资金
- Ministry of Education, Science, Sports and Culture, Ministry of Health, Labor, and Welfare, Japan
- Grants-in-Aid for Scientific Research [24591442, 21679005, 24659401] Funding Source: KAKEN
We identified the domains of CD26 involved in the binding of Middle East respiratory syndrome coronavirus (MERS-CoV) using distinct clones of anti-CD26 monoclonal antibodies (MAbs). One clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 MAb YS110 also significantly inhibited infection. These findings indicate that both 2F9 and YS110 are potential therapeutic agents for MERS-CoV infection. YS110, in particular, is a good candidate for immediate testing as a therapeutic modality for MERS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据